Drug Profile
R 554
Alternative Names: R-554Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Radikal Therapeutics
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury; Brain injuries; Reperfusion injury
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Inhalation, Aerosol)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Reperfusion-injury(Prevention) in USA (Inhalation, Aerosol)
- 29 Nov 2019 Preclinical development for Acute lung injury (smoke inhalation injury) is ongoing in USA (Inhalation, Aerosol) (Radikal Therapeutics pipeline, November 2019)